Boyracı Neslihan, Önür Seda Tural, Kara Kaan, Akyıl Fatma Tokgoz, Abalı Hülya, Kocaoğlu Aslı, Sökücü Sinem Nedime, Altın Sedat, Pehlivan Sacide, Oyacı Yasemin
Department of Chest Diseases, Health Sciences University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
Department of Chest Diseases, Health Sciences University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
Am J Med Sci. 2024 Nov;368(5):438-445. doi: 10.1016/j.amjms.2024.06.006. Epub 2024 Jun 13.
Pulmonary Thromboembolism (PTE) occurs as a result of occlusion of one or more of the pulmonary artery branches by thrombus and is an important cause of right heart failure and pulmonary hypertension. Selenoprotein P (SePP) and soluble suppression of tumorigenicity 2 protein (sST2) are two new biomarkers that have previously been the subject of various studies in heart failure. The aim of this study was to determine the diagnostic and prognostic potential of SePP and soluble sST2 levels in patients with acute PTE.
The study included 135 patients diagnosed with acute non-massive PTE and 43 healthy volunteers. Clinical, laboratory, and radiological patient data were recorded. SePP and sST2 levels were measured in the patient and control groups. Patients were followed at 1, 3, and 6 months of treatment via the death notification system and telemedicine.
SePP and sST2 levels were significantly lower in the patient group compared with the control group (SePP: 17.65 ng/ml vs. 43.06 ng/ml and sST2: 10.86 ng/ml vs. 16.20 ng/ml, both p < 0.001). No correlation was found at 1, 3, and 6 months of follow-up with prognosis and mortality.
SePP and sST2 values were significantly lower in patients with acute PTE compared with the control group. Low levels of these biomarkers may be diagnostically valuable.
肺血栓栓塞症(PTE)是由于一个或多个肺动脉分支被血栓阻塞所致,是右心衰竭和肺动脉高压的重要原因。硒蛋白P(SePP)和可溶性肿瘤抑制因子2蛋白(sST2)是两种新的生物标志物,此前已成为心力衰竭各种研究的对象。本研究的目的是确定SePP和可溶性sST2水平在急性PTE患者中的诊断和预后潜力。
本研究纳入135例诊断为急性非大面积PTE的患者和43名健康志愿者。记录患者的临床、实验室和影像学数据。测定患者组和对照组的SePP和sST2水平。通过死亡通知系统和远程医疗对患者进行1、3和6个月的治疗随访。
与对照组相比,患者组的SePP和sST2水平显著降低(SePP:17.65 ng/ml对43.06 ng/ml,sST2:10.86 ng/ml对16.20 ng/ml,均p<0.001)。在随访的1、3和6个月时,未发现与预后和死亡率相关。
与对照组相比,急性PTE患者的SePP和sST2值显著降低。这些生物标志物水平较低可能具有诊断价值。